VVL-TD-RFP

VVL-TD-RFP is a genetically engineered oncolytic vaccinia virus (VV) derived from the Lister strain (VVL). It is characterized by the triple deletion of the thymidine kinase (TK), N1L, and A41L genes, and it incorporates a red fluorescent protein (RFP) reporter gene under the control of the H5 promoter. The deletion of the TK and N1L genes enhances tumor selectivity and safety, while the deletion of the A41L gene, which encodes a soluble chemokine-binding protein, prevents the virus from interfering with host chemokine-mediated leukocyte migration. This modification significantly increases the infiltration of dendritic cells, natural killer cells, and CD8+ effector memory T cells into the tumor microenvironment. VVL-TD-RFP is primarily investigated as a therapeutic agent and a viral backbone for pancreatic cancer, demonstrating the ability to remodel "cold" immunosuppressive tumors into "hot" immunogenic ones and serving as a platform for further arming with therapeutic cytokines like IL-27.

Other names

VVLΔTKΔN1LΔA41L-RFPA41L-deleted VVL-TD-RFPA-41L-deleted VVL-TD-RFPA 41L-deleted VVL-TD-RFPVVL-TD